secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000950170-25-070286
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna completes SPS Phase 2 enrollment; BLA filing now 1H 2026; Q1 net loss $44.6M
--------------------------------------------------------------------------------

- Enrollment completed in KYSA-8 pivotal Phase 2 trial of KYV-101 in stiff person syndrome; topline data 1H 2026.
- BLA filing for KYV-101 in SPS accelerated to 1H 2026 (from prior 2026 guidance).
- FDA aligns on registrational Phase 3 for myasthenia gravis; interim Phase 2 data expected 2H 2025.
- Cash and equivalents $242.6M; runway into 2027 supports first BLA, Phase 3 MG, and pre-launch activities.
- Workforce reduced ~16% in Q1 2025; Q1 net loss $44.6M ($1.03/shr) vs $26.7M ($1.12/shr) in Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000095017025070286/0000950170-25-070286-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000095017025070286/kytx-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-070286

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer